Vasu Divi, MD
Otolaryngology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Divi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121464 · Current
Licensed to practise in California · since 2012 · expires 2028-01-31 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$172,232
Medicare paid this office $172,232 for 180 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of lymph nodes, muscle, and tissue of neck | 18 | $21,546 | $1,197 |
| Repair of wound by transferring skin, each additional 30.0 sq cm | 17 | $10,927 | $171 |
| Repair of wound by transferring skin, 30.1-60.0 sq cm | 20 | $8,745 | $437 |
| Partial thickness self skin graft to face, scalp, eyelids, mouth, neck, ears, around eyes, genitals, hands, feet, fingers, or toes, 100.0 sq cm or 1% body area for infants and children, or less | 16 | $6,747 | $422 |
| New patient visit (45+ min) | 44 | $5,135 | $117 |
See all 12 services
| Removal of lymph nodes, muscle, and tissue of neck | 18 | $21,546 | $1,197 |
| Repair of wound by transferring skin, each additional 30.0 sq cm | 17 | $10,927 | $171 |
| Repair of wound by transferring skin, 30.1-60.0 sq cm | 20 | $8,745 | $437 |
| Partial thickness self skin graft to face, scalp, eyelids, mouth, neck, ears, around eyes, genitals, hands, feet, fingers, or toes, 100.0 sq cm or 1% body area for infants and children, or less | 16 | $6,747 | $422 |
| New patient visit (45+ min) | 44 | $5,135 | $117 |
| Short return visit (20+ min) | 74 | $4,508 | $54 |
| Partial thickness self skin graft to trunk, arms, or legs, 100.0 sq cm or 1% body area for infants and children, or less | 12 | $4,492 | $346 |
| New patient visit (60+ min) | 19 | $3,086 | $162 |
| Long return visit (40+ min) | 11 | $1,435 | $130 |
| Return visit (30+ min) | 12 | $1,334 | $83 |
| Short return visit (20+ min) | 13 | $1,149 | $88 |
| Punch biopsy, first skin growth | 12 | $485 | $40 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 24 | More than 77% of doctors who do this |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
180 Original Medicare patients in 2024. Average age 77 · Women 34% · Also on Medicaid 14% · Health risk score 1.88. Sicker patients than 9 in 10 peers; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 69% · Coronary heart disease 34% · Chronic kidney disease 31% · Diabetes 25% · Atrial fibrillation 24% · Heart failure 18% · Cancer 18% · Depression 17% · COPD 14% · Stroke 9% · Dementia 7%.
The office billed $2,087,890, Medicare allowed $217,182 and paid $172,232; for 519 services of 84 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 180 | 519 | 77 | 1.88 | $2,087,890 | $172,232 |
| 2023 | 166 | 449 | 77 | 1.70 | $1,705,390 | $149,093 |
| 2022 | 136 | 334 | 75 | 1.63 | $1,181,701 | $121,151 |
| 2021 | 151 | 396 | 74 | 1.64 | $1,174,350 | $130,984 |
| 2020 | 125 | 331 | 75 | 1.91 | $1,133,347 | $122,055 |
| 2019 | 165 | 493 | 75 | 1.98 | $1,384,223 | $158,083 |
| 2018 | 143 | 434 | 75 | 1.73 | $1,027,185 | $127,417 |
| 2017 | 111 | 393 | 74 | 2.05 | $1,057,995 | $114,854 |
| 2016 | 122 | 369 | 74 | 2.23 | $906,931 | $104,631 |
| 2015 | 107 | 309 | 74 | 2.39 | $756,498 | $86,412 |
| 2014 | 91 | 350 | 74 | 2.08 | $956,198 | $118,187 |
| 2013 | 76 | 307 | 74 | 1.72 | $750,214 | $100,719 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Removal of lymph nodes, muscle, and tissue of neck | 26 | $33,743 | $1,298 |
| Repair of wound by transferring skin, 30.1-60.0 sq cm | 16 | $7,231 | $452 |
| Short return visit (20+ min) | 85 | $6,184 | $56 |
| New patient visit (45+ min) | 42 | $5,155 | $123 |
| New patient visit (60+ min) | 17 | $2,839 | $167 |
| Return visit (30+ min) | 13 | $1,174 | $90 |
| Punch biopsy, first skin growth | 13 | $566 | $38 |
2022: 5 services
| Removal of lymph nodes, muscle, and tissue of neck | 19 | $17,602 | $926 |
| Short return visit (20+ min) | 64 | $4,205 | $57 |
| New patient visit (45+ min) | 25 | $3,004 | $120 |
| New patient visit (60+ min) | 14 | $2,362 | $169 |
| Short return visit | 29 | $740 | $24 |
2021: 8 services
| Skin graft with repair of small blood vessel | 12 | $27,640 | $1,974 |
| Removal of lymph nodes, muscle, and tissue of neck | 12 | $12,205 | $1,017 |
| Extensive removal of growth of face or scalp, 2.0 cm or more | 14 | $8,563 | $612 |
| Short return visit (20+ min) | 77 | $5,998 | $54 |
| New patient visit (45+ min) | 35 | $4,297 | $123 |
| Partial thickness self skin graft to trunk, arms, or legs, 100.0 sq cm or 1% body area for infants and children, or less | 11 | $3,770 | $343 |
| New patient visit (30+ min) | 13 | $928 | $71 |
| Short return visit | 32 | $880 | $27 |
2020: 6 services
| Skin graft with repair of small blood vessel | 14 | $29,142 | $2,082 |
| Removal of lymph nodes, muscle, and tissue of neck | 18 | $20,443 | $1,136 |
| Short return visit (20+ min) | 68 | $3,304 | $40 |
| New patient visit (60+ min) | 20 | $2,977 | $149 |
| New patient visit (45+ min) | 12 | $1,443 | $120 |
| Short return visit | 20 | $484 | $22 |
2019: 10 services
| Removal of lymph nodes, muscle, and tissue of neck | 21 | $23,290 | $1,059 |
| Skin graft with repair of small blood vessel | 12 | $20,553 | $1,713 |
| Repair of wound by transferring skin, 30.1-60.0 sq cm | 11 | $5,355 | $487 |
| Partial thickness self skin graft to trunk, arms, or legs, 100.0 sq cm or 1% body area for infants and children, or less | 13 | $4,676 | $360 |
| Short return visit (20+ min) | 73 | $4,167 | $40 |
| New patient visit (45+ min) | 33 | $3,703 | $112 |
| New patient visit (60+ min) | 13 | $1,980 | $152 |
| Short return visit | 64 | $1,626 | $22 |
| Return visit (30+ min) | 17 | $1,292 | $72 |
| Diagnostic exam of voice box using a flexible endoscope | 15 | $854 | $53 |
2018: 7 services
| Skin graft with repair of small blood vessel | 11 | $24,177 | $1,727 |
| Removal of lymph nodes, muscle, and tissue of neck | 18 | $19,813 | $1,101 |
| Short return visit (20+ min) | 89 | $6,680 | $43 |
| New patient visit (45+ min) | 27 | $2,835 | $105 |
| New patient visit (60+ min) | 14 | $2,016 | $144 |
| Diagnostic exam of voice box using a flexible endoscope | 24 | $1,595 | $51 |
| Return visit (30+ min) | 18 | $1,272 | $71 |
2017: 7 services
| Removal of lymph nodes, muscle, and tissue of neck | 16 | $17,447 | $1,090 |
| Extensive removal of growth of face or scalp, 2.0 cm or more | 11 | $7,904 | $659 |
| Partial thickness self skin graft to face, scalp, eyelids, mouth, neck, ears, around eyes, genitals, hands, feet, fingers, or toes, 100.0 sq cm or 1% body area for infants and children, or less | 15 | $5,771 | $361 |
| Short return visit (20+ min) | 77 | $5,386 | $40 |
| New patient visit (45+ min) | 23 | $2,368 | $103 |
| Diagnostic exam of voice box using a flexible endoscope | 22 | $1,721 | $57 |
| Return visit (30+ min) | 11 | $585 | $53 |
2016: 6 services
| Removal of lymph nodes, muscle, and tissue of neck | 13 | $18,166 | $1,397 |
| Short return visit (20+ min) | 77 | $6,200 | $43 |
| New patient visit (45+ min) | 21 | $2,333 | $111 |
| New patient visit (60+ min) | 13 | $1,946 | $150 |
| Diagnostic exam of voice box using a flexible endoscope | 18 | $1,397 | $67 |
| Long return visit (40+ min) | 11 | $1,090 | $99 |
2015: 3 services
| Extensive removal of growth of face or scalp, 2.0 cm or more | 13 | $8,824 | $679 |
| Short return visit (20+ min) | 72 | $5,446 | $44 |
| New patient visit (45+ min) | 18 | $1,963 | $109 |
2014: 7 services
| Skin graft with repair of small blood vessel | 15 | $27,699 | $1,847 |
| Removal of lymph nodes, muscle, and tissue of neck | 11 | $13,301 | $1,209 |
| Extensive removal of growth of face or scalp, 2.0 cm or more | 11 | $7,466 | $622 |
| Partial thickness self skin graft to trunk, arms, or legs, 100.0 sq cm or 1% body area for infants and children, or less | 15 | $5,239 | $349 |
| Short return visit (20+ min) | 61 | $4,827 | $41 |
| New patient visit (45+ min) | 13 | $1,503 | $116 |
| Diagnostic exam of voice box using a flexible endoscope | 11 | $1,207 | $60 |
2013: 5 services
| Removal of lymph nodes, muscle, and tissue of neck | 11 | $11,489 | $1,044 |
| Repair of wound by transferring skin, 30.1-60.0 sq cm | 11 | $5,954 | $496 |
| Short return visit (20+ min) | 42 | $3,261 | $43 |
| New patient visit (45+ min) | 21 | $2,375 | $113 |
| Diagnostic exam of voice box using a flexible endoscope | 19 | $1,957 | $70 |
Money from drug and device companies
$20,705 in 2025
| 2025 | 2 | 18 | $18,155 | $20,705 |
| 2024 | 5 | 14 | $9,856 | $11,037 |
| 2023 | 1 | 4 | None | $4,600 |
| 2022 | 2 | 14 | $9,776 | $11,667 |
| 2019 | 1 | 1 | $2,520 | $2,520 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Libtayo | $18,774 | 17 payments
|
| Ethicon US | Vicryl | $1,931 | 1 payment
|
See all 18 published payments
| Ethicon US | Consulting · 2025-11-13 | Vicryl | $1,931 |
| Regeneron Healthcare Solutions | Consulting · 2025-05-30 | Libtayo | $832 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-21 | Libtayo | $832 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-21 | Libtayo | $6,656 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-21 | Libtayo | $7,488 |
| Regeneron Healthcare Solutions | Travel · 2025-03-21 | Libtayo | $65 |
| Regeneron Healthcare Solutions | Travel · 2025-03-21 | Libtayo | $64 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Libtayo | $416 |
| Regeneron Healthcare Solutions | Travel · 2025-02-26 | Libtayo | $495 |
| Regeneron Healthcare Solutions | Meals · 2025-02-26 | Libtayo | $41 |
| Regeneron Healthcare Solutions | Meals · 2025-02-26 | Libtayo | $108 |
| Regeneron Healthcare Solutions | Meals · 2025-02-26 | Libtayo | $51 |
| Regeneron Healthcare Solutions | Meals · 2025-02-26 | Libtayo | $46 |
| Regeneron Healthcare Solutions | Meals · 2025-02-26 | Libtayo | $106 |
| Regeneron Healthcare Solutions | Travel · 2025-02-18 | Libtayo | $253 |
| Regeneron Healthcare Solutions | Travel · 2025-02-18 | Libtayo | $161 |
| Regeneron Healthcare Solutions | Travel · 2025-01-14 | Libtayo | $1,003 |
| Regeneron Healthcare Solutions | Travel · 2025-01-14 | Libtayo | $160 |
See earlier years (2024, 2023, 2022, 2019)
2024: $11,037
| Regeneron Pharmaceuticals | Libtayo | $10,044 | 10 payments
|
| Regeneron Healthcare Solutions | Libtayo | $832 | 1 payment
|
| Stryker | Core | $73 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $47 | 1 payment
|
| DePuy Synthes Sales | Trumatch | $41 | 1 payment
|
2023: $4,600
| Regeneron Pharmaceuticals | Libtayo | $4,600 | 4 payments
|
2022: $11,667
| Regeneron Pharmaceuticals | Libtayo | $11,399 | 12 payments
|
| Baxter Healthcare | None | $268 | 2 payments
|
2019: $2,520
| Regeneron Pharmaceuticals | Libtayo | $2,520 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II To IV (M0) Cutaneous Squamous Cell Carcinoma (Cscc) · 2023 | Their institution | $365,903 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II To IV (M0) Cutaneous Squamous Cell Carcinoma (Cscc) · 2021 | Their institution | $212,780 |
| Genentech, Inc. · Neoadjuvant Atezolizumab for Advanced Cutaneous Scc · 2023 | Their institution | $171,524 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma · 2024 | Their institution | $166,620 |
| Genentech, Inc. · Neoadjuvant Atezolizumab for Advanced Cutaneous Scc · 2024 | Their institution | $152,950 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II To IV (M0) Cutaneous Squamous Cell Carcinoma (Cscc) · 2022 | Their institution | $115,766 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma · 2025 | Their institution | $89,603 |
| Merck Sharp & Dohme LLC · A Phase 2,3, Adaptive, Randomized, Open-Label, Clinical Study To Evaluate Neoadjuvant and Adjuvant V940 Mrna-4157 in Combination With Pembrolizumab Mk-3475 Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma La Cscc Interpath-007 · 2024 | Their institution | $66,420 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II To IV (M0) Cutaneous Squamous Cell Carcinoma (Cscc) · 2024 | Their institution | $58,338 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II To IV (M0) Cutaneous Squamous Cell Carcinoma (Cscc) · 2025 | Their institution | $53,230 |
| Genentech, Inc. · Neoadjuvant Atezolizumab for Advanced Cutaneous Scc · 2022 | Their institution | $30,315 |
| Genentech, Inc. · Neoadjuvant Atezolizumab for Advanced Cutaneous Scc · 2021 | Their institution | $13,184 |
| Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2022 | This clinician | $2,126 |
| Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2024 | This clinician | $559 |
| Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2023 | This clinician | $536 |
| Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2025 | This clinician | $192 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1750407334
- Licence
- CA A121464, MI 4301083303California A121464: Current · expires 2028-01-31
- Trained
- University of Michigan Medical School, 2004
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207YX0905X (207YX0905X); Otolaryngology (207Y00000X); Student in a training program (390200000X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2007-03-22
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.